RxDoctor Payments Data

Rickay Wolf, APRN

Psychiatric/Mental Health · Gillette, WYNPI 1023486016

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 38.9% of the total. 2024 is the largest year on record at $301, 6.1 times the $49 reported in 2022.

$518in general payments, 2019–2025

Across 28 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$201
  • AbbVie$141
  • Lundbeck LLC$66
  • Alkermes, Inc.$42
  • Ironshore Pharmaceuticals Inc.$27
  • Neurocrine Biosciences, Inc.$21
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$518 in reported general payments places this provider in the 60th percentile of 76 psychiatric/mental health providers in Wyoming.

See all psychiatric/mental health providers in Wyoming

Medicare billing

Part B allowed, 2024
$2,845
Medicare patients
12
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CymbaltaDuloxetine Hcl12$5,969
Duloxetine Hcl22$288
Quetiapine Fumarate11$172
Trazodone Hcl22$165

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Gillette

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →